trending Market Intelligence /marketintelligence/en/news-insights/trending/3b4gXcyR9Gerr2WH3kPqgA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie psoriasis drug Skyrizi gets 1st approval in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AbbVie psoriasis drug Skyrizi gets 1st approval in Japan

AbbVie Inc. said Skyrizi received its first country approval from Japan's Ministry of Health, Labour and Welfare to treat adults with certain forms of psoriasis.

Skyrizi, or risankizumab, can now be used in Japan to treat plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies.

Psoriasis is a chronic, immune-mediated disease characterized by raised, red, scaly patches on the skin.

The approval was supported by the effectiveness and safety data from mid- and late-stage trials — sustaIMM, ultIMMa-1 and IMMspire — which evaluated Skyrizi in Japanese patients with the disease. A global mid-stage study among patients with active psoriatic arthritis also backed the Japanese health agency's decision.

On March 1, the European Medicines Agency recommended the approval of Skyrizi for treating moderate to severe psoriasis.

AbbVie said it is looking at Skyrizi, together with upadacitinib, to replace its best-selling immunology drug Humira which is facing biosimilar competition.

Boehringer Ingelheim GmbH and AbbVie are collaborating on Skyrizi.